An observational study in Atopic Dermatitis, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-10-12.
Sponsored by Northwestern University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Dermatitis, Atopic by Northwestern University — 2 open to participants now, 3 under way, none of them phase 3. Dermatitis, Atopic · Northwestern University.
Among the 16 studies in Dermatitis, Atopic by Northwestern University, this one is the only one that started in 2017, is one of 6 observational ones, and was the 9th registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies in Dermatitis, Atopic by Northwestern University are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
Northwestern University · Sites in United States
Ages 2+
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2017.
This study's enrollment of 46 is below the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 29 across the 10 interventional studies, 109 across the 6 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
2 of the studies in Dermatitis, Atopic by Northwestern University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07050810Northwestern UniversityThera-Clean® Microbubbles System in Patients With Skin Diseases | 2027-06 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Dermatitis, Atopic by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.
The investigators will conduct a prospective, longitudinal, non-interventional and observational sub-study of patients receiving dupilumab as normal standard-of-care treatment to assess the efficacy (Specific Aim #1) and safety (Specific Aim #2) of dupilumab for the treatment of moderate-to-severe AD, as well as the prevention and/or mitigation of comorbid health conditions (Specific Aim #3). This study will address the hypotheses that dupilumab will lead to improved long-term control and decreased severity of AD, and that long-term monitoring will shed light on the incidence of adverse drug events.
Patients diagnosed with moderate-to-severe atopic dermatitis on dupilumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
Biological: Dupilumab
Biologic (monoclonal antibody)
Also known as: Dupixent
Quantified Itch Survey
Time frame: 1 to 3 months
Quantified Sleep Survey
Time frame: 1 to 3 months
Quantified Quality of Life Survey
Time frame: 1 to 3 months
Occurrence of any AEs by 24 months
Will be determined based off of patient reported safety events
Time frame: 24 months
Occurrence of any infections by 24 months
Will be determined based off of patient reported safety events
Time frame: 24 months
Occurrence of any SAEs by 24 months
Will be determined based off of patient reported safety events
Time frame: 24 months
Ran from Oct 2017 to primary completion in Aug 2019, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.